It's a new year, but there's the same increasing demand for Abbott's COVID-19 tests as the virus continues surging across the globe and people are ready to get back to normalcy. To address the growing demand, Abbott continues to ramp-up its manufacturing capacity to meet the world's needs. And now that Abbott fulfilled the federal government's order of 150 million BinaxNOW COVID-19 tests, the company is ready to make tens of millions of the tests available each month for organizations, including schools, workplaces and pharmacies. Analysts expect demand for COVID-19 testing to continue climbing through the new year. 'We see the potential for a 'durable tail' of diagnostic revenue that should persist long after a vaccine is available (into 2022 and beyond), with the potential to mirror annual flu testing volumes in perpetuity,' said Morgan Stanley analysts in a Dec. 10, 2020, note.1 Abbott's COVID-19 test innovations were spotlighted at the virtual Consumer Electronics Show (CES) during the COVID-19 State of the Union session on Jan. 12 with Andrea Wainer, Executive Vice President, Rapid and Molecular Diagnostics at Abbott. CES is the world's most influential technology event and health tech has become an important and growing part of the conference, as digital technology plays an increasingly critical role in healthcare. Abbott was invited to participate because of the testing technologies the company has developed and distributed at mass scale to help tackle the pandemic and get people back to normalcy.